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Abstract
Purpose: According to guidelines, to shorten the treatment window, acute ischaemic stroke (AIS) treatment by intra­
venous thrombolysis (IVT) can be done based on the results of head computed tomography (CT) without contrast. 
The impact of large vessel occlusion (LVO) on computed tomography angiography (CTA) in stroke prognosis in 
patients treated IVT or IVT and mechanical thrombectomy (MT), where indicated, has not yet been studied systema­
tically. We investigated the influence of LVO in consecutive AIS patients on haemorrhagic transformation (HT) on 
CT 24 h after treatment, mRS < 2 on discharge (unfavourable outcome), and in­hospital mortality.
Material and methods: We analysed several parameters within 24 h after AIS: demographics, risk factors, mRS score 
pre­stroke, NIHSS upon admission and 24 h later, several clinical and biochemical parameters, and chronic treat­
ment. 
Results: We registered 1209 patients, of whom 362 (29.9%) received IVT and 108 had MT, where indicated. Admis­
sion CTA showed LVO in 197 patients (54.4%). Multivariate regression analysis showed that the presence of LVO 
and lower delta NIHSS (NIHSS on admission minus NIHSS 24 hours later) were independent parameters affecting 
HT risk. Multivariate analysis showed that the presence LVO and also older age, female sex, lower delta NIHSS, 
HT, stroke­associated infection, CRP levels ≥ 10 mg/L, and higher WBC count affected unfavourable outcome on 
discharge. LVO did not affect in­hospital mortality. 
Conclusions: LVO in AIS patients treated by IVT or IVT and MT affects the risk of HT and unfavourable short­term 
outcome but not in­hospital mortality.
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Introduction 
Intravenous thrombolysis (IVT) by rt­PA or tenecteplase 
is the only effective pharmacological treatment for acute 
ischaemic stroke (AIS) [1,2]. Unfortunately, this treatment 
is efficient only in a small proportion of patients [3]. Time 
from stroke onset to treatment by IVT is thought to be the 
most important factor affecting IVT efficacy [3]. Accord­
ing to guidelines, to save time, the treatment of AIS by 
IVT can be done based on the results of head computed 
tomography (CT) without contrast [1,2]. A few studies, 
additionally implementing computed tomography angio­
graphy (CTA), have shown that large vessel occlusion 
(LVO) is an important poor prognostic factor in patients 
with AIS, irrespective of whether they are being treated 
[4­6] or not treated by IVT [7].
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In recent years, mechanical thrombectomy (MT) has 
become a recommended treatment option for patients 
with LVO [8­12]. Key studies showing the effectiveness 
of MT in AIS indicated the advantage of brain vessel 
neuroimaging before the treatment procedure to show 
detailed LVO location [8­12]. In our Stroke Unit, we in­
troduced a complex neuroimaging protocol on admission, 
including computed tomography (CT) with and without 
contrast and CTA, in all consecutive AIS patients, irre­
spectively of their treatment perspective and whether or 
not they declared any history of chronic renal disease. 
The protocol allowed us to gather immediately data on the 
presence of LVO, its location, or the presence of vascu­
lar malformations. All this information allows easier and 
safer decision­making about AIS treatment and smoother 
patient flow during the therapeutic window. 
In this study, we analysed the frequency and the influ­
ence of LVO on admission CTA in consecutive patients 
treated by IVT or IVT and MT, where indicated, on short­
term outcome measures (i.e. haemorrhagic transforma­
tion [HT] on CT 24 h after treatment, poor outcome as 
measured by the mRS 3­6 on discharge, and in­hospital 
mortality).
Material and methods
We retrospectively analysed the data prospectively col­
lected in the Krakow Stroke Data Bank (KSDB). The KSDB 
is a single­centre, hospital­based registry in which clinical, 
radiological, and genetic data from AIS cases are includ­
ed. The systematic collection of data was started in 2007. 
The study design was approved by the Jagiellonian Univer­
sity Ethical Committee (KBET 54/B/2007). The diagnosis of 
stroke was made according to the definition by Sacco et al. 
[13]. The collected patient information has been described 
in detail elsewhere [14]. For the purpose of the present 
study, we analysed data from participants of KSDB treat­
ed with IVT from June 2014 to December 2018. In each 
included patient we analysed the following data available 
within 24 h after stroke: demographics (age and sex); stroke 
risk factors (hypertension, diabetes mellitus, ischaemic 
heart disease, atrial fibrillation, hypercholesterolaemia, 
smoking status, body mass index, and history of stroke); 
clinical parameters (prestroke independence as measured 
by the modified Rankin Score [mRS]) [15] (we distin­
guished patients with mRS = 0 [no disability] from those 
with mRS > 0 [at least slight disability]); body temperature 
on admission (we distinguished patients with body tem­
perature ≥ 37°C and with body temperature < 37°C); time 
from stroke onset to alteplase infusion; and maximum sys­
tolic blood pressure and diastolic blood pressures within 
24 hours after alteplase infusion. We distinguished patients 
with maximal systolic blood pressure > 160 mm Hg and 
≤ 160 mm Hg (160 mm Hg was the median value); and 
patients with maximal diastolic blood pressure > 85 mm 
Hg and ≤ 85 mm Hg (85 mm Hg was the median value). 
Stroke severity was measured on admission and 24 hours 
later according to the National Institutes of Health Stroke 
Scale (NIHSS) [16]. Delta NIHSS was defined as the dif­
ference between NIHSS score measured upon hospital 
admission minus the NIHSS score 24 hours after alteplase 
infusion (lower scores reflect deterioration; higher scores 
indicate improvement). We also examined post­treatment 
haemorrhagic complications on CT taken 24 hours post­
stroke (categorized as patients with or without bleeding) 
and stroke aetiology according to the Trial of Org10172 
in acute Stroke Treatment (TOAST) criteria [17]. We also 
analysed the presence and location of LVO shown on CTA 
performed on admission. We analysed LVO location. We 
also distinguished patients with and without LVO on CTA 
in large vessels of the brain.
We collected data on the use of antibiotics during hos­
pitalization due to stroke­associated infection (SAI) (we 
distinguished those with and without SAI). The details 
about the diagnosis of infections have been reported else­
where [18].
Biochemical data taken while fasting on the 1st day 
morning were as follows: CRP levels (increased CRP levels 
was diagnosed as CRP ≥ 10 mg/l); white blood cells (WBC) 
count; fibrinogen levels; haemoglobin levels; platelet count; 
glucose levels; creatinine levels, TSH, total cholesterol lev­
els, LDL­cholesterol levels, HDL­cholesterol levels, and tri­
glycerides levels.
We analysed the following early outcome measures: 
post­treatment haemorrhagic transformation (HT) on 
computed tomography (CT) taken 24 h after stroke (we 
distinguished patients with or without bleeding). The in­
tensity of bleeding was evaluated according to the ECASS 
II criteria [19]. Unfavourable outcome on discharge was 
defined as mRS score [15] from 3 to 6. We also analysed 
the in­hospital death rate. 
Statistical analysis
Clinical characteristics and outcomes between the groups 
were compared by the unpaired Student t­test or c2 test, 
where appropriate. To identify potential independent pre­
dictors of outcome, variables with p­value < 0.05 in the 
univariate regression analysis for the presence of brain 
haemorrhage, unfavourable outcome as measured by mRS 
score from 3 to 6, or death on discharge were subsequently 
included into a multivariate regression analysis. All statisti­
cal calculations were performed by Statistica software ver­
sion 13.3 (TIBCO software INC). P­values below 0.05 were 
considered statistically significant. 
Results
During the study period, 1209 patients registered with the 
KSDB and 362 (29.9%) received IVT. CTA revealed LVO in 
197 patients (54.4%), and 108 patients had MT performed, 
where indicated. In detail, 46 patients out of 362 (12.7%) 
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Table 2. Multivariate regression models analysing parameters affecting risk of haemorrhagic transformation on CT (model including or excluding CRP and WBC count), 
factors affecting unfavourable short-term outcome (mRS: 3-6) and in hospital mortality (mRS = 6)
Parameter OR 95% CI p-value
Parameters affecting risk of haemorrhage on CT taken 24 hours after alteplase 
infusion
Demographics
Age (years) 0.99 0.97-1.01 0.29
Sex (females) 0.87 0.48-1.60 0.65
Stroke risk factors
 Atrial fibrillation 1.90 0.99-3.62 0.05
Hypercholesterolemia 0.67 0.35-1.27 0.22
Clinical parameters
 Large vessel occlusion on admission 
angio-CT
3.60 1.93-6.71 0.000053
Delta NIHSS 0,92 0.88-0.96 0.00011
Biochemical parameters
 Glucose levels (mmol/l) 1.09 0.99-1.19 0.07
 Platelet count (µl) 0.70 0.46-1.08 0.11
Parameters affecting unfavourable outcome on discharge
Demographics
Age (years) 1.06 1.02-1.09 0.0011
Sex (females) 2.47 1.17-5.22 0.02
Stroke risk factors
 Hypertension (mm Hg) 2.80 0.83-9.41 0.09
Atrial fibrillation 0.82 0.38-1.80 0.62
Body mass index (kg/m2) 1.05 0.96-1.14 0.28
History of stroke 1.21 0.50-2.94 0.66
Clinical parameters
Modified Rankin scale score before stroke > 0 3.13 0.97-10.12 0.05
Body temperature ≥ 37.0oC on admission 0.29 0.07-1.19 0.08
Maximal systolic blood pressure within  
24 hours after stroke > 160 mm Hg
1.54 0.72-3.29 0.26
Maximal diastolic blood pressure within  
24 hours after stroke > 85 mm Hg 
0.78 0.34-1.77 0.55
Delta NIHSS 0.87 0.78-0.90 0.00000022
Large vessel occlusion on admission 
angio-CT
3.12 1.48-6.54 0.0026
Haemorrhagic transformation on CT  
24 hours after admission
6.40 2.75-14.88 0.000015
Treatment
Antibiotic treatment due to stroke-
associated infection, n (%)
3.83 1.73-8.51 0.00093
Biochemical parameters
CRP ≥ 10 (mg/l) 3.70 1.81-7.54 0.00031
White blood cells count (µl) 1.13 1.01-1.26 0.04
Glucose levels (mmol/l) 0.99 0.88-1.12 0.84
LDL (mmol/l) 0.77 0.31-1.93 0.59
Parameter OR 95% CI p-value
Parameters affecting unfavourable outcome on discharge without CRP,  
and WBC count
Demographics
Age (years) 1.05 1.02-1.09 0.0013
Sex (females) 2.44 1.21-4.91 0.01
Stroke risk factors
Hypertension (mm Hg) 3.01 0.93-9.67 0.06
Atrial fibrillation 0.79 0.37-1.68 0.54
Body mass index (kg/m2) 1.05 0.97-1.14 0.22
History of stroke 1.20 0.52-2.74 0.67
Clinical parameters
Modified Rankin Score before stroke > 0 2.97 0.99-8.89 0.05
Body temperature ≥ 37.0°C on admission 0.40 0.10-1.53 0.18
Maximal systolic blood pressure within 
24 hours after stroke > 160 mm Hg
0.64 0.29-1.44 0.28
Maximal diastolic blood pressure within 
24 hours after stroke > 85 mm Hg 
1.45 0.71-2.98 0.31
Delta NIHSS 0.84 0.78-0.90 0.00000030
Large vessel occlusion on admission 
angio-CT
3.68 1.28-7.45 0.00027
Haemorrhagic transformation on CT  
24 hours after admission
4.93 2.25-10.78 0.000061
Treatment
Antibiotic treatment due to stroke-
associated infection, n (%)
5.88 2.79-12.40 0.0000030
Biochemical parameters
Glucose levels (mmol/l) 1.02 0.91-1.13 0.75
LDL (mmol/l) 0.69 0.30-1.61 0.39
Parameters affecting the risk of death at discharge 
Demographics
Age (years) 1.03 0.97-1.08 0.34
Sex (females) 2.58 0.86-7.79 0.09
Clinical parameters
Modified Rankin scale score before 
stroke > 0
9.56 2.47-37.03 0.0010
Delta NIHSS 0.78 0.71-0.86 0.0000014
Large vessel occlusion on admission 
angio-CT
1.57 0.55-4.45 0.40




Antibiotic treatment due to stroke-
associated infection, n (%)
0.96 0.32-2.86 0.94
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had LVO in the symptomatic carotid artery. Among these, 
18 (39.1%) had IVT, and 28 (60.9%) had IVT and sub­
sequent MT. In 91 patients (25.1%), LVO was in the M1 
region of the symptomatic middle cerebral artery (MCA). 
Among these, 36 (39.7%) had IVT, and 55 (60.3%) had IVT 
and MT. In 36 patients (9.9%), LVO was in the M2 region 
of symptomatic MCA. Among these, 21 (58.4%) had IVT, 
and 15 (41.6%) had IVT and subsequent MT. In 8 patients 
(2.2%), LVO was in the M3 region of symptomatic MCA. 
Among these, 6 (75%) had IVT, and 2 (25%) had IVT and 
MT. In 16 patients (4.4%), LVO was in the symptomatic 
basilar artery. Among these, 8 cases had IVT and 8 had IVT 
plus MT. In 128 patients (35.6%), CTA did not show LVO, 
and in another 37 patients (10.2%) CTA showed arterial 
atherosclerotic changes in brain arteries without AC.
Haemorrhagic transformation on CT taken 24 h after 
stroke was found in 75 patients. According to the ECASS 
II classification, 25 patients (6.9%) developed small pete­
chiae within the infarcted area, 24 patients (6.6%) had more 
confluent petechiae within the infarcted area, 14 (3.9%) 
had haemorrhage not exceeding 30% of the infarcted area 
with some mild space­occupying effect, and 12 (3.3%) had 
brain haemorrhage exceeding 30% of the infarct volume 
with significant space­occupying effect. Groups of patients 
with and without HT did not differ with respect to age and 
sex distribution. Univariate analysis showed that LVO on 
admission CTA, AF, hypercholesterolaemia, lower delta 
NIHSS, higher platelet count, and higher glucose levels 
correlated with HT (Table 1). Multivariate analysis showed 
that LVO on admission CTA and lower delta NIHSS were 
independent factors that affected HT risk (Table 2).
In total 147 patients (40.5%) had an unfavourable out­
come, as measured by mRS: 3­6 on discharge. Univariate 
analysis showed that these patients were significantly older 
and more often female, more often had LVO on admission 
CTA, had higher incidence rates of hypertension and AF, 
had higher body mass index (kg/m2), were more likely to 
have a history of stroke, more often had body temperature 
≥ 37°C on admission, and more often maximal systolic blood 
pressure > 160 mm Hg and maximal diastolic blood pressure 
> 85 mm Hg within 24 h after stroke. Patients with unfa­
vourable outcomes were more likely to have mRS scores 
above 0 pre­stroke or HT on CT, had lower NIHSS than 
those with a favourable outcome, were more likely to re­
quire treatment with antibiotics due to SAI, and were more 
likely to have CRP levels ≥ 10 mg/l, higher WBC counts, and 
higher glucose and lower LDL­cholesterol levels (Table 1). 
Multivariate analysis showed that the presence LVO 
on admission CTA, older age, female sex, lower delta 
NIHSS, HT on CT taken 24 h post­stroke, antibiotic treat­
ment due to SAI, more likely CRP levels ≥ 10 mg/l, and 
higher WBC count affected unfavourable outcome on dis­
charge (Table 2).
Multivariate analysis, excluding CRP levels and WBC 
count (inflammatory markers), showed a similar profile 
of factors affecting unfavourable outcome on discharge 
(i.e. LVO, older age, female sex, lower delta NIHSS, HT on 
CT taken 24 h post­stroke, antibiotic treatment due to SAI) 
(Table 2). 
Thirty­four (9.4%) of the patients died before dis­
charge. Patients who died were older and more likely to be 
female. Univariate analysis showed that they more often 
had LVO on admission CTA. Compared to their surviving 
counterparts, patients who died were more likely to score 
above 0 on the mRS before the stroke, had lower delta 
NIHSS, and presented more frequently with HT on CT 
taken with 24 h post­treatment. They were also signifi­
cantly more likely to use antibiotic treatment due to SAI. 
Concerning the biochemical parameters, they presented 
with CRP levels ≥ 10 mg/l more often and had lower tri­
glyceride levels (Table 1). 
Multivariate analysis showed that an mRS above 0 before 
admission, lower delta NIHSS, HT on CT taken 24 h after 
IVT, and CRP levels ≥ 10 mg/l were independent factors that 
affected the risk of death up to discharge. Multivariate analy­
sis after the exclusion of CRP did not change the profile of 
independent factors affecting in­hospital mortality (Table 2).
Discussion
We found that in patients with AIS treated by IVT solely or 
IVT and MT, where indicated according to current recom­
mendations [1,2], the presence of LVO on admission CTA 
Biochemical markers
CRP ≥ 10 (mg/l) 3.11 1.08-8.93 0.03
 TG (mmol/l) 0.30 0.08-1.12 0.07
Parameters affecting risk of death at discharge, without CRP
Demographics
Age (years) 1.03 0.98-1.09 0.21
Sex (males) 2.40 0.81-7.06 0.11
Clinical parameters
modified Rankin scale score before 
stroke > 0
8.75 2.36-32.44 0.0011
Delta NIHSS 0.79 0.72-0.87 0.0000020
Large vessel occlusion on admission 
angio-CT
1.75 0.63-4.86 0.28




Antibiotic treatment due to stroke-
associated infection, n (%)
1.38 0.50-3.81 0.53
Biochemical parameters
TG (mmol/l) 0.35 0.11-1.17 0.09
NIHSS – National Institute of Health Stroke Scale, CRP – C-reactive protein, TG – triglycerides, LDL – low- 
density lipoprotein, CT – computed tomography
Parameter OR 95% CI p-value
Table 2. Cont.
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was an independent factor affecting the risk of HT on CT 
taken 24 h after stroke and unfavourable outcome on dis­
charge as measured by the mRS: 3­6, but not in­hospital 
mortality. 
A few studies performed in patients treated by IVT solely 
[4,5] or IVT and intraarterial thrombolysis as bridging thera­
py [6], before the era of MT, indicated that the LVO on CTA 
affected poor prognosis. The prognostic significance of the 
presence of LVO on admission CTA in consecutive patients 
treated by IVT or IVT and MT, where indicated, was not 
studied systematically. 
According to guidelines, to shorten the time win­
dow, the treatment of AIS by IVT can be done based on 
the results of the head CT without contrast. Our results 
strengthen the need to perform additionally admission 
CTA of the brain arteries to show the presence and ex­
act location of LVO in the brain artery. This knowledge is 
not only helpful in preparing individual treatment plans 
but also, based on the results of the present study, in pre­
dicting short­term prognosis. We would like to empha­
size that in our Stroke Unit, in an emergency setting, to 
shorten the therapeutic window maximally and based on 
current guidelines [1,2], we do not measure creatinine 
levels routinely on admission. Only patients who report 
chronic renal failure on admission have their neuroimag­
ing procedures scheduled individually, after evaluation of 
the blood parameters of renal efficiency and a consulta­
tion with a nephrologist. In all other patients, creatinine 
levels are routinely studied on the next morning after the 
admission. In the presented group of patients, we record­
ed a mean creatinine level of 84.4 ± 25.8 µmol/l (median 
value, 81 µmol/l; IQR, 68­97 µmol/l; min­max values, 
27 and 218 µmol/l). In patients with creatinine levels out­
side the normal range, consultation with a nephrologist 
was routinely scheduled, and treatment was introduced. 
Nobody from the presented group required dialysis.
Haemorrhagic transformation on CT in AIS patients 
treated by IVT as an early outcome measure was analysed 
previously by several authors [20­33]. Most of these were 
analysed as symptomatic haemorrhage according to ECASS 
II criteria (i.e. the presence of any haemorrhage on CT not 
detected on previous CT, combined with neurological dete­
rioration of 4 points or more in NIHSS from baseline) [19]. 
The prevalence of symptomatic haemorrhages in the studies 
varied from 3.9% [27] to 8.4% [23]. In our study, we were 
able to find only 12 symptomatic haemorrhages according to 
the above­mentioned criteria (3.3%), and we were not able 
to find any significant differences between patients with and 
without symptomatic haemorrhage (data not shown). When 
we compared patients with and without HT on CT taken 
24 h after stroke, despite taking into account any concomi­
tant changes in neurological deficit, in a multivariate regres­
sion analysis, we found that LVO and deterioration of the 
neurological deficit after treatment affected its risk. Interest­
ingly, our results are in line with previous studies published 
on this topic [20,29­31], showing the correlation of symp­
tomatic brain haemorrhage with neurological deficit. 
In our study, we also measured 2 different early out­
come measures: unfavourable outcome (defined as the 
mRS from 3 to 6 on discharge) and in­hospital mortality. 
Interestingly, many different early outcome measures were 
studied so far in AIS patients treated by IVT, such as the 
following: early recanalization [22,34], in­hospital mortal­
ity [30,35], in­hospital mortality or discharge to a nurs­
ing home [29], neurological deterioration as measured 
by an increase of NIHSS by at least 4 points 24 h after 
stroke [24,29,36], at least by 8 points on day 7 after stroke 
[24,29], or deterioration by at least 2 points between day 
0 and 5 [21], and mRS on discharge [37]. In those stud­
ies, most of the authors analysed the influence of a single 
chosen parameter on the studied early outcome measure. 
For example, Kimura et al. showed that AF is the only 
factor influencing the lack of recanalization, and the lack 
of recanalization correlated with neurological worsening 
[34]. Sung et al. showed that mortality on discharge in 
severe stroke was similar in those with and without AF 
[30]. Jovanowic et al. showed that early outcome measures 
are similar in males and females [24], while Al Husain 
confirmed the lack of correlation between sex and recana­
lization rate [22]. Tang confirmed that diabetes mellitus 
affects unfavourable outcomes 24 h after stroke, and on 
day 7 after stroke [29]. Only 2 authors were able to build 
up logistic regression models showing independent fac­
tors affecting in­hospital mortality (age ≥ 80 years, apha­
sia, conscious disturbances, hypertension, the presence 
of haemorrhage on CT, and pneumonia) [20,29] and in­
hospital mortality or discharge to a nursing facility (older 
age, longer hospital stay, and large cerebral infarct) [38]. 
In our study, we showed that unfavourable outcome as 
measured by mRS: 3­6 on discharge, but not in­hospital, is 
affected by the presence of LVO on admission CTA; lower 
delta NIHSS and HT on CT taken 24 h after stroke are 
common disadvantageous factors affecting both outcome 
measures in the present study. Unfavourable outcome was 
also related with antibiotic treatment due SAI, irrespec­
tively of including or excluding markers of inflamma­
tion into logistic regression models. Interestingly, as was 
shown previously [39], age and sex affected the unfavour­
able outcome but not in­hospital mortality. 
Our study is mainly limited by its retrospective analy­
sis. The risk of selection bias is possible because we in­
cluded only patients who agreed to participate in the 
study. We also analysed outcome measures on discharge, 
and, unfortunately, we did not collect detailed informa­
tion about the length of hospital stay; in Poland, patients 
with AIS are hospitalized for at least 9 days or until death. 
Another limitation is the relatively long recruitment pe­
riod, lasting 5 years, so this long period might increase the 
number of confounding factors because the approach to 
stroke treatment changes rapidly over time. 
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Conclusions
In AIS patients treated by IVT solely or by IVT and MT, 
where indicated according to current guidelines, LVO of 
the brain vessels shown on admission CTA affects the risk 
of HT or unfavourable outcome on discharge, but not in­
hospital mortality.
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